Advertisement
CLPT vs NVST
Which Stock Would AI Choose? ClearPoint Neuro (CLPT) vs. Envista Holdings (NVST) Stock Comparison
Key Takeaways
- CLPT is a small-cap medical device company enabling drug, cell, and gene therapy delivery to the brain and spine, while NVST is a global, mid-to-large-cap dental products company.
- ClearPoint Neuro is growing revenue rapidly but remains unprofitable; Envista is profitable and recently raised its 2026 earnings guidance.
- Both stocks trade well below their 52-week highs, and both have seen analyst price-target reductions in recent weeks.
- CLPT offers higher growth potential tied to biopharma partnerships, while NVST offers more established scale and positive cash flow.
- Risk profiles differ sharply: CLPT carries clinical, regulatory, and funding risk, while NVST faces tariff, China pricing, and currency headwinds.
Introduction
Investors evaluating healthcare stocks often weigh high-growth, early-stage medical technology against established, profitable franchises. This stock comparison examines two very different companies: CLPT (ClearPoint Neuro, Inc.), a small-cap neurosurgical navigation and drug-delivery specialist, and NVST (Envista Holdings Corporation), a diversified dental products leader. Understanding their relative performance, market positioning, and risk profiles can help growth-oriented traders and value-minded investors alike assess where each fits in a portfolio under current market conditions.
CLPT Overview and Recent Performance
ClearPoint Neuro, Inc. (CLPT) is a commercial-stage medical device company that provides precision navigation systems for minimally invasive procedures in the brain and spine. Its technology supports drug, cell, and gene therapy delivery, and it partners with more than 60 active biopharma companies across numerous clinical trials.
In recent quarters, CLPT has delivered strong top-line momentum. Revenue grew 43% year over year in the most recent quarter to roughly $12.1 million, supported in part by the integration of the IRRAS acquisition completed in late 2025. Gross margin expanded to 64%, reflecting favorable inventory dynamics. However, the company remains unprofitable, posting a wider operating loss as research and development, and sales and marketing expenses increased substantially. Management trimmed its full-year revenue outlook to approximately $48 million to $52 million, citing a deliberate investment phase and capacity ramp-up at its new preclinical services facility.
Sentiment has been mixed. The share price has softened meaningfully from its 52-week high, and several analysts lowered price targets in recent weeks while largely retaining buy ratings. A securities-law firm announcement regarding a potential investor investigation also surfaced recently, adding to near-term uncertainty around the stock.
NVST Overview and Recent Performance
Envista Holdings Corporation (NVST) is a global dental products company uniting more than 30 brands, including DEXIS imaging, Kerr consumables, Nobel Biocare implants, and Ormco orthodontics. It operates across two segments: Specialty Products & Technologies and Equipment & Consumables.
NVST has shown a strengthening earnings recovery in recent quarters. In its most recent quarter, adjusted earnings per share (EPS) rose sharply year over year, supported by margin expansion and solid core sales growth. Management raised its full-year 2026 guidance, now projecting adjusted EPS in a higher range and faster adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) growth. Core growth has been broad-based, led by consumables, diagnostics, and the Spark clear-aligner franchise.
Still, headwinds persist. Tariff costs have increased, and China's volume-based procurement program for implants is expected to pressure pricing. Foreign currency movements also affect results, given that a majority of revenue comes from outside the United States. In recent weeks, several firms lowered price targets on NVST, though the overall analyst consensus remains favorable and one major bank upgraded the stock to an Overweight rating earlier in the period.
Trending AI Robots
Tickeron maintains hundreds of AI Trading Bots that monitor and trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance record, and set of securities. Because market conditions shift constantly, only a select group of bots earns a place in the curated Trending AI Robots section. These featured bots are identified as the most suitable for the current market environment, with many displaying measurable statistics such as trade frequency, win rates, and historical performance ranges. Whether a trader prefers short-term momentum or longer-horizon positioning, the platform offers a range of approaches. Explore the Trending AI Robots page to see which automated strategies are currently leading.
Head-to-Head Comparison
The two companies differ fundamentally in business model and stage. ClearPoint Neuro is a capital-light but still loss-making innovator whose growth depends on biopharma trial activity, regulatory approvals, and adoption of cell and gene therapies. Envista is a scaled, cash-generating manufacturer with an installed base of imaging systems and recurring consumable demand across global dental practices.
Growth drivers diverge as well. CLPT's upside is tied to the expansion of its biopharma partner network and new product categories, giving it potentially higher, but less predictable, growth. NVST's growth is more incremental, driven by new product launches, share gains in clear aligners, and productivity from its operating system.
On momentum and sentiment, both stocks have faced downward pressure in recent weeks and trade below their highs. CLPT's valuation reflects a revenue multiple with no current earnings, whereas NVST trades at a forward earnings multiple near its own historical median. Risk factors also contrast: CLPT faces clinical, regulatory, and cash-burn risk, while NVST faces tariff, foreign-exchange, and China pricing exposure.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor NVST on the basis of trend consistency and stability. Envista's profitable operations, positive free-cash-flow conversion, and upward earnings guidance offer a more reliable, measurable trajectory for trend-following algorithms. ClearPoint Neuro's higher growth rate and substantial analyst upside target are attractive, but its unprofitability, wider losses, and recent price-target reductions introduce greater volatility and less predictable signals. Accordingly, a probabilistic AI assessment would tilt toward NVST for relative positioning in the current environment, while recognizing CLPT as a higher-risk, higher-reward alternative that may become more favorable if catalysts materialize.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLPT is a StrongBuy and NVST is a Buy.
CLPT's RSI Oscillator recovers from oversold territory
The RSI Oscillator for CLPT moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 28 of the 34 cases the stock moved higher. This puts the odds of a move higher at 82%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 16 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +4.19% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLPT advanced for three days, in 216 of 271 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
CLPT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLPT as a result. In 82 of 96 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
The Moving Average Convergence Divergence Histogram (MACD) for CLPT turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 45 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
CLPT moved below its 50-day moving average on September 29, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLPT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for CLPT entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLPT's P/B Ratio (26.184) is slightly higher than the industry average of (2.874). P/E Ratio (-7.839) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (9.268) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. CLPT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLPT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
NVST's RSI Oscillator recovers from oversold territory
The RSI Indicator for NVST moved out of oversold territory on October 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 19 of the 27 cases the stock moved higher. This puts the odds of a move higher at 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on NVST as a result. In 69 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for NVST just turned positive on October 06, 2026. Looking at past instances where NVST's MACD turned positive, the stock continued to rise in 34 of 51 cases over the following month. The odds of a continued upward trend are 67%.
Following a +4.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where NVST advanced for three days, in 176 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 70%.
NVST broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NVST entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. NVST’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 63 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.211) is normal, around the industry mean (4.961). P/E Ratio (39.305) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.451) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
CLPT | NVST | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 31 Undervalued | 63 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 87 | |
PRICE GROWTH RATING 1..100 | 87 | 58 | |
P/E GROWTH RATING 1..100 | 14 | 82 | |
SEASONALITY SCORE 1..100 | 90 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CLPT's Valuation (31) in the null industry is in the same range as NVST (63). This means that CLPT’s stock grew similarly to NVST’s over the last 12 months.
CLPT's Profit vs Risk Rating (100) in the null industry is in the same range as NVST (100). This means that CLPT’s stock grew similarly to NVST’s over the last 12 months.
NVST's SMR Rating (87) in the null industry is in the same range as CLPT (100). This means that NVST’s stock grew similarly to CLPT’s over the last 12 months.
NVST's Price Growth Rating (58) in the null industry is in the same range as CLPT (87). This means that NVST’s stock grew similarly to CLPT’s over the last 12 months.
CLPT's P/E Growth Rating (14) in the null industry is significantly better than the same rating for NVST (82). This means that CLPT’s stock grew significantly faster than NVST’s over the last 12 months.
| CLPT | NVST | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 82% | 1 day ago 70% |
| Stochastic ODDS (%) | 1 day ago 82% | 1 day ago 79% |
| Momentum ODDS (%) | 1 day ago 85% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 83% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 86% | 1 day ago 67% |
| TrendMonth ODDS (%) | 1 day ago 85% | 1 day ago 72% |
| Advances ODDS (%) | 3 days ago 80% | 1 day ago 64% |
| Declines ODDS (%) | 9 days ago 87% | 4 days ago 70% |
| BollingerBands ODDS (%) | 1 day ago 69% | 1 day ago 76% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CLPT’s FA Score shows that 2 FA rating(s) are green while NVST’s FA Score has 0 green FA rating(s).
- CLPT’s FA Score: 2 green, 3 red.
- NVST’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CLPT’s TA Score shows that 4 TA indicator(s) are bullish while NVST’s TA Score has 4 bullish TA indicator(s).
- CLPT’s TA Score: 4 bullish, 5 bearish.
- NVST’s TA Score: 4 bullish, 4 bearish.
Price Growth
CLPT (@Medical/Nursing Services) experienced а -4.05% price change this week, while NVST (@Pharmaceuticals: Other) price change was +2.00% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.50%. For the same industry, the average monthly price growth was -10.64%, and the average quarterly price growth was -10.25%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.59%. For the same industry, the average monthly price growth was -3.91%, and the average quarterly price growth was +7.47%.
Reported Earning Dates
CLPT is expected to report earnings on Oct 28, 2026.
NVST is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (-1.50% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+0.59% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
CLPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, CLPT has been loosely correlated with ICUI. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if CLPT jumps, then ICUI could also see price increases.
| Ticker / NAME | Correlation To CLPT | 1D Price Change % | ||
|---|---|---|---|---|
| CLPT | 100% | N/A | ||
| ICUI - CLPT | 57% Loosely correlated | +4.66% | ||
| ISRG - CLPT | 46% Loosely correlated | +3.67% | ||
| A - CLPT | 45% Loosely correlated | -2.17% | ||
| NVST - CLPT | 45% Loosely correlated | +3.36% | ||
| SMTI - CLPT | 43% Loosely correlated | +0.34% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IYG | 94.43 | 0.71 | +0.76% |
| iShares US Financial Services ETF (IYG) | |||
| SMDX | 25.94 | N/A | N/A |
| Intech S&P Small-Mid Cap Diversified Alpha ETF | |||
| FDAT | 21.95 | -0.12 | -0.54% |
| Tactical Advantage ETF (FDAT) | |||
| DDLS | 44.42 | -0.38 | -0.84% |
| WisdomTree Dynamic International SmallCap Equity Fund (DDLS) | |||
| WDNA | 23.18 | -0.34 | -1.44% |
| WisdomTree BioRevolution Fund (WDNA) | |||